| Phase 110 trials |
|
Phase 1
|
NCT06712173 |
Dec 2024 → Sep 2025 overdue |
peripheral T-cell lymphoma, not otherwise specified |
Institute of Hematology & Blood Diseases Hospital, China |
Not yet recruiting
|
No outcome recorded
|
|
Phase 1
|
NCT06093945 |
Nov 2023 |
cancer |
Jiangsu HengRui Medicine Co., Ltd. |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT06010680 |
Oct → Nov 2023 |
lymphoma |
Jiangsu HengRui Medicine Co., Ltd. |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT05661591 |
Feb → Mar 2023 |
cancer |
Jiangsu HengRui Medicine Co., Ltd. |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT05592262 |
Nov → Dec 2022 |
cancer |
Jiangsu HengRui Medicine Co., Ltd. |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT05049083 |
Dec 2021 → Jan 2022 |
lymphoma |
Jiangsu HengRui Medicine Co., Ltd. |
Unknown
|
No outcome recorded
|
|
Phase 1
|
NCT04627129 |
Jun → Oct 2020 |
— |
Jiangsu HengRui Medicine Co., Ltd. |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT04577885 |
May → Aug 2020 |
— |
Jiangsu HengRui Medicine Co., Ltd. |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT04335266 |
Aug → Sep 2019 |
— |
Jiangsu HengRui Medicine Co., Ltd. |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT03603951 |
Aug 2018 → Feb 2026 overdue |
lymphoid neoplasm |
Jiangsu HengRui Medicine Co., Ltd. |
Active not recruiting
|
No outcome recorded
|
| Phase 1/28 trials |
|
Phase 1/2
|
NCT07615283 |
May 2026 → May 2030 expected |
mature T-cell and NK-cell non-Hodgkin lymphoma, peripheral T-cell lymphoma, not otherwise specified |
Sun Yat-sen University |
Not yet recruiting
|
No outcome recorded
|
|
Phase 1/2
|
NCT06568094 |
Sep 2024 → Dec 2026 expected |
prostate cancer |
Jiangsu HengRui Medicine Co., Ltd. |
Recruiting
|
No outcome recorded
|
|
Phase 1/2
|
NCT06173999 |
Dec 2023 → Dec 2025 |
peripheral T-cell lymphoma, not otherwise specified |
Jiangsu HengRui Medicine Co., Ltd. |
Unknown
|
No outcome recorded
|
|
Phase 1/2
|
NCT05896046 |
Jun 2023 → Jun 2025 |
Hodgkins lymphoma |
Chinese PLA General Hospital |
Unknown
|
No outcome recorded
|
|
Phase 1/2
|
NCT05559008 |
Sep 2022 → Mar 2024 |
peripheral T-cell lymphoma, not otherwise specified |
Ruijin Hospital |
Unknown
|
No outcome recorded
|
|
Phase 1/2
|
NCT04407741 |
Sep 2020 → Dec 2024 |
cancer, lymphoma |
Chinese PLA General Hospital |
Unknown
|
No outcome recorded
|
|
Phase 1/2
|
NCT03741712 |
Nov 2018 → Sep 2019 |
castration-resistant prostate carcinoma |
Jiangsu HengRui Medicine Co., Ltd. |
Terminated
|
No outcome recorded
|
|
Phase 1/2
|
NCT03805399 |
Oct 2018 → Dec 2022 |
triple-negative breast carcinoma |
Fudan University |
Unknown
|
No outcome recorded
|
| Phase 212 trials |
|
Phase 2
|
NCT07575412 |
Jun 2026 → Jun 2029 expected |
acute lymphoblastic leukemia, acute myeloid leukemia, myelodysplastic syndrome |
The First Affiliated Hospital of Soochow University |
Not yet recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT07562568 |
Jun 2026 → Jun 2030 expected |
acute lymphoblastic leukemia, acute myeloid leukemia, myelodysplastic syndrome |
The First Affiliated Hospital of Soochow University |
Not yet recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT07347288 |
Feb 2026 → Feb 2029 expected |
— |
The First Affiliated Hospital with Nanjing Medical University |
Not yet recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT07230106 |
Dec 2025 → Dec 2028 expected |
prostate cancer |
Jiangsu HengRui Medicine Co., Ltd. |
Recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT07175220 |
Oct 2025 → Oct 2028 expected |
non-small cell lung carcinoma |
Jiangsu HengRui Medicine Co., Ltd. |
Recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT07125950 |
Sep 2025 → Sep 2027 expected |
breast cancer |
Henan Cancer Hospital |
Not yet recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT07102901 |
Sep 2025 → Dec 2027 expected |
gastric cancer, gastroesophageal junction adenocarcinoma |
Jiangsu HengRui Medicine Co., Ltd. |
Recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT07294664 |
Jun 2025 → Jul 2027 expected |
gastric cancer |
The First Affiliated Hospital of Zhengzhou University |
Recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT06679673 |
Dec 2024 → Dec 2025 overdue |
colorectal cancer |
Fudan University |
Not yet recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT06519526 |
Aug 2024 → Feb 2027 expected |
peripheral T-cell lymphoma, not otherwise specified |
Fudan University |
Recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT06368167 |
Apr 2024 → Apr 2027 expected |
follicular lymphoma |
Jiangsu HengRui Medicine Co., Ltd. |
Not yet recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT04355858 |
May 2020 → May 2023 |
breast cancer, metastatic malignant neoplasm |
Fudan University |
Unknown
|
No outcome recorded
|
|
| Phase 31 trial |
|
Phase 3
|
NCT06122389 |
Feb 2024 → May 2026 overdue |
peripheral T-cell lymphoma, not otherwise specified |
Jiangsu HengRui Medicine Co., Ltd. |
Recruiting
|
No outcome recorded
|
| Comparator or background therapy1 trial |
|
Phase 2
|
NCT07311408 Comparator |
Jan 2026 → Jan 2028 expected |
gastric cancer, gastroesophageal junction adenocarcinoma |
Jingdong Zhang |
Recruiting
|
No outcome recorded
|